CP 544326: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 18376177 |
| CHEMBL ID | 2107783 |
| SCHEMBL ID | 3318549 |
| MeSH ID | M0569393 |
| Synonym |
|---|
| bdbm50016953 |
| taprenepag |
| 752187-80-7 |
| taprenepag (usan/inn) |
| D09968 |
| 2-(3-((((4-(1h-pyrazol-1-yl)phenyl)methyl)(pyridin-3-ylsulfonyl)amino) methyl)phenoxy)acetic acid |
| cp 544326 |
| acetic acid, 2-(3-((((4-(1h-pyrazol-1-yl)phenyl)methyl)(3-pyridinylsulfonyl)amino) methyl)phenoxy)- |
| 9cd894kumj , |
| cp-544326 |
| unii-9cd894kumj |
| pf 04217329 |
| taprenepag [usan:inn] |
| CHEMBL2107783 |
| gtpl5816 |
| 2-[3-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]phenoxy]acetic acid |
| SCHEMBL3318549 |
| pf04217329 |
| taprenepag [usan] |
| taprenepag [who-dd] |
| 2-(3-((n-((4-(1h-pyrazol-1-yl)phenyl)methyl)pyridine-3-sulfonamido)methyl)phenoxy)acetic acid |
| taprenepag [inn] |
| cp544326 |
| acetic acid, (3-((((4-(1h-pyrazol-1-yl)phenyl)methyl)(3-pyridinylsulfonyl)amino)methyl)phenoxy)- |
| acetic acid, 2-(3-((((4-(1h-pyrazol-1-yl)phenyl)methyl)(3-pyridinylsulfonyl)amino)methyl)phenoxy)- |
| 2-(3-{[{[4-(1h-pyrazol-1-yl)phenyl]methyl}(pyridin-3-ylsulfonyl)amino]methyl}phenoxy)acetic acid |
| DTXSID00226187 |
| CS-5590 |
| HY-14899 |
| J-690347 |
| EX-A941 |
| acetic acid, [3-[[[[4-(1h-pyrazol-1-yl)phenyl]methyl](3-pyridinylsulfonyl)amino]methyl]phenoxy]- |
| mfcd18633300 |
| AKOS030632799 |
| taprenepag(cp-544326) |
| DB12623 |
| A858259 |
| BCP17228 |
| BCP24232 |
| Q27088938 |
| 2-(3-((n-(4-(1h-pyrazol-1-yl)benzyl)pyridine-3-sulfonamido)methyl)phenoxy)acetic acid |
| 2-[3-[[[[4-(1h-pyrazol-1-yl)phenyl]methyl](3-pyridinylsulfonyl)amino]methyl]phenoxy]acetic acid; cp 544326 |
| AS-76944 |
| 2-[3-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonyl-amino]methyl]phenoxy]ethanoic acid |
| GNO , |
| CFB18780 |
| 2-(3-((n-(4-(1h-pyrazol-1-yl)benzyl)pyridine-3-sulfonamido)methyl)phenoxy)aceticacid |
| AC-36845 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "8 nM) whose corneal permeability and ocular bioavailability were significantly increased when the compound was dosed as the isopropyl ester prodrug, PF-04217329." | ( Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma. Almaden, C; Anderson, S; Carreiro, S; Dinh, D; Fortner, J; Gale, D; Gukasyan, H; Krauss, A; Lafontaine, J; Niesman, M; Prasanna, G; Sartnurak, S; Toris, C; Wells, P; Xiang, C; Younis, H, 2011) | 0.37 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "8 nM) whose corneal permeability and ocular bioavailability were significantly increased when the compound was dosed as the isopropyl ester prodrug, PF-04217329." | ( Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma. Almaden, C; Anderson, S; Carreiro, S; Dinh, D; Fortner, J; Gale, D; Gukasyan, H; Krauss, A; Lafontaine, J; Niesman, M; Prasanna, G; Sartnurak, S; Toris, C; Wells, P; Xiang, C; Younis, H, 2011) | 0.37 |
| "Monkeys were dosed daily for 28 days in 1 eye with taprenepag and in the other with vehicle control." | ( Investigation of ocular events associated with taprenepag isopropyl, a topical EP2 agonist in development for treatment of glaucoma. Affolter, T; Eighmy, JJ; Evans, MG; Jessen, BA; Khoh-Reiter, S; Lee, D; Miller, PE; Shiue, MH; Trajkovic, D; Yanochko, GM, 2014) | 0.4 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) | Ki | 3.2000 | 0.0091 | 0.6635 | 1.5849 | AID1151360 |
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | Ki | 3.2000 | 0.0001 | 0.4744 | 3.1623 | AID1151362 |
| Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | Ki | 3.2000 | 0.0003 | 1.7081 | 6.8000 | AID1151361 |
| Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | Ki | 0.0100 | 0.0010 | 0.5448 | 3.0000 | AID1151359 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | EC50 (µMol) | 0.0028 | 0.0019 | 0.9665 | 7.8000 | AID1151368 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| D1 dopamine receptor binding | Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) |
| prostaglandin E receptor activity | Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) |
| prostaglandin E receptor activity | Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) |
| protein binding | Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) |
| prostaglandin E receptor activity | Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) |
| prostaglandin E receptor activity | Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) |
| plasma membrane | Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) |
| plasma membrane | Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) |
| membrane | Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) |
| plasma membrane | Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) |
| nuclear envelope | Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) |
| plasma membrane | Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) |
| membrane | Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) |
| plasma membrane | Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) |
| plasma membrane | Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) |
| plasma membrane | Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1151362 | Binding affinity to EP4 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151373 | Selectivity ratio of Ki for EP4 receptor (unknown origin) to Ki for EP2 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151369 | Agonist activity at prostanoid IP receptor (unknown origin) by functional assay | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151372 | Selectivity ratio of Ki for EP3 receptor (unknown origin) to Ki for EP2 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151359 | Binding affinity to EP2 receptor (unknown origin) by competitive binding assay | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151361 | Binding affinity to EP3 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151368 | Agonist activity at EP2 receptor (unknown origin) by functional assay | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151363 | Binding affinity to prostanoid IP receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151371 | Selectivity ratio of Ki for EP1 receptor (unknown origin) to Ki for EP2 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1151360 | Binding affinity to EP1 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Prostanoid receptor EP2 as a therapeutic target. |
| AID1346318 | Rat EP2 receptor (Prostanoid receptors) | 2011 | Experimental eye research, Sep, Volume: 93, Issue:3 | Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma. |
| AID1346308 | Human EP2 receptor (Prostanoid receptors) | 2011 | Experimental eye research, Sep, Volume: 93, Issue:3 | Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.31) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (33.33%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (50.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||